171 related articles for article (PubMed ID: 11513188)
41. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy.
Campbell MS; Brensinger CM; Sanyal AJ; Gennings C; Wong F; Kowdley KV; McCashland T; Reddy KR
Hepatology; 2005 Sep; 42(3):635-40. PubMed ID: 16108073
[TBL] [Abstract][Full Text] [Related]
42. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.
Campillo B; Sherman E; Richardet JP; Bories PN
Eur J Clin Nutr; 2001 Nov; 55(11):980-8. PubMed ID: 11641747
[TBL] [Abstract][Full Text] [Related]
43. Transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension using memotherm stents: a prospective multicenter study.
Domagk D; Patch D; Dick R; Grosso M; Rousseau H; Otal P; Goffette P; Heinecke A; Drees M; Domschke W; Menzel J
Cardiovasc Intervent Radiol; 2002; 25(6):506-12. PubMed ID: 12183763
[TBL] [Abstract][Full Text] [Related]
44. Torulopsis glabrata fungemia from infected transjugular intrahepatic portosystemic shunt stent.
Brickey TW; Trotter JF; Johnson SP
J Vasc Interv Radiol; 2005 May; 16(5):751-2. PubMed ID: 15872333
[TBL] [Abstract][Full Text] [Related]
45. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE).
Guglielmi FW; Panella C; Buda A; Budillon G; Caregaro L; Clerici C; Conte D; Federico A; Gasbarrini G; Guglielmi A; Loguercio C; Losco A; Martines D; Mazzuoli S; Merli M; Mingrone G; Morelli A; Nardone G; Zoli G; Francavilla A
Dig Liver Dis; 2005 Sep; 37(9):681-8. PubMed ID: 15978878
[TBL] [Abstract][Full Text] [Related]
46. [Transjugular intrahepatic portosystemic stent-shunts or paracentesis in the treatment of cirrhotic patients with refractory ascites].
Ainsworth MA; Nielsen OH
Ugeskr Laeger; 2005 Aug; 167(35):3273-6. PubMed ID: 16138966
[No Abstract] [Full Text] [Related]
47. First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan.
Tsuruya K; Koizumi J; Sekiguchi Y; Ono S; Sekiguchi T; Hara T; Mishima Y; Arase Y; Hirose S; Shiraishi K; Kagawa T
BMJ Open Gastroenterol; 2023 Apr; 10(1):. PubMed ID: 37085275
[TBL] [Abstract][Full Text] [Related]
48. Utility of transjugular intrahepatic portosystemic shunts in liver-transplant recipients.
Choi DX; Jain AB; Orloff MS
J Am Coll Surg; 2009 Apr; 208(4):539-46. PubMed ID: 19476787
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of TIPS in patients with hemophilia and cirrhosis.
Beirne JP; Bloom AI; Bass NM; Kerlan RK; Wilson MW; Gordon RL; Laberge JM
J Vasc Interv Radiol; 2007 Feb; 18(2):309-12. PubMed ID: 17327567
[TBL] [Abstract][Full Text] [Related]
50. The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis.
Therapondos G; Hol L; Benjaminov F; Wong F
Hepatology; 2006 Sep; 44(3):640-9. PubMed ID: 16941706
[TBL] [Abstract][Full Text] [Related]
51. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism.
Thomsen KL; Sandahl TD; Holland-Fischer P; Jessen N; Frystyk J; Flyvbjerg A; Grønbæk H; Vilstrup H
Clin Nutr; 2012 Dec; 31(6):940-5. PubMed ID: 22541535
[TBL] [Abstract][Full Text] [Related]
52. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts.
Gülberg V; Liss I; Bilzer M; Waggershauser T; Reiser M; Gerbes AL
Digestion; 2002; 66(2):127-30. PubMed ID: 12428073
[TBL] [Abstract][Full Text] [Related]
53. Successful treatment of refractory ascites in a child with transjugular intrahepatic portosystemic shunt.
Lee WS; McKiernan PJ; de Ville de Goyet JV; Tanner MS; John PR
Acta Paediatr; 2001 Nov; 90(11):1352-5. PubMed ID: 11808914
[TBL] [Abstract][Full Text] [Related]
54. Clotting activation after transjugular intrahepatic portosystemic stent shunt.
Basili S; Merli M; Ferro D; Lionetti R; Rossi E; Riggio O; Valeriano V; Capocaccia L; Violi F
Thromb Haemost; 1999 May; 81(5):711-4. PubMed ID: 10365742
[TBL] [Abstract][Full Text] [Related]
55. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis.
Biecker E; Roth F; Heller J; Schild HH; Sauerbruch T; Schepke M
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):846-52. PubMed ID: 17873607
[TBL] [Abstract][Full Text] [Related]
56. Modified saphenous-peritoneal shunt in refractory ascites: new technique.
Chen JH; Liu HD; Yu JC; Chen CJ; Shih ML; Liu YC; Hsieh CB
ANZ J Surg; 2005 Mar; 75(3):128-31. PubMed ID: 15777390
[TBL] [Abstract][Full Text] [Related]
57. Resting energy expenditure of children and adolescents undergoing hemodialysis.
Marques de Aquino T; Avesani CM; Brasileiro RS; de Abreu Carvalhaes JT
J Ren Nutr; 2008 May; 18(3):312-9. PubMed ID: 18410889
[TBL] [Abstract][Full Text] [Related]
58. Complications following transjugular intrahepatic portosystemic shunt: a retrospective analysis.
Silva RF; Arroyo PC; Duca WJ; Silva AA; Reis LF; Cabral CM; Sgnolf A; Domingues RB; Barao GT; Coelho DJ; Deberaldini M; Felício HC; Silva RC
Transplant Proc; 2004 May; 36(4):926-8. PubMed ID: 15194319
[TBL] [Abstract][Full Text] [Related]
59. Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism.
Plauth M; Schütz T; Buckendahl DP; Kreymann G; Pirlich M; Grüngreiff S; Romaniuk P; Ertl S; Weiss ML; Lochs H
J Hepatol; 2004 Feb; 40(2):228-33. PubMed ID: 14739092
[TBL] [Abstract][Full Text] [Related]
60. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
